Watchlist Price Alert

Novartis AG (NVS)

NYSE: NVS · Real-Time Price · USD

113.15

-1.14 (-1.00%)

At close: May 05, 2025, 12:21 PM

-1.00% (1D)

Bid	113.12
Market Cap	223.48B
Revenue (ttm)	52.86B
Net Income (ttm)	12.86B
EPS (ttm)	6.38
PE Ratio (ttm)	17.74
Forward PE	12.64
Analyst	Hold

Ask	113.15
Volume	692,592
Avg. Volume (20D)	2,441,178
Open	114.10
Previous Close	114.29
Day's Range	112.70 - 114.16
52-Week Range	96.06 - 120.92
Beta	0.55

About NVS

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops,...

[Read more]

Industry Drug Manufacturers - General

Sector Healthcare

IPO Date Nov 7, 1996

Employees 75,883

Stock Exchange NYSE

Ticker Symbol NVS

Website https://www.novartis.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for NVS stock is "Hold." The 12-month stock price forecast is $121, which is an increase of 6.94% from the latest price.

Stock Forecasts

Earnings Surprise

Novartis has released their quartely earnings on Apr 29, 2025:

Revenue of $13.23B exceeds estimates by $243M, with 11.87% YoY growth.

EPS of 2.28 exceeds estimates by 0.20, with 26.67% YoY growth.

Why Price Moved

3 weeks ago

+3.98%

Novartis shares are trading higher after the compa... Unlock content with Pro Subscription

6 months ago

-4.41%

Novartis shares are trading lower. The company reported Q3 financial results

News

Just now · reuters.com

BioNTech says Novartis executive Zapata-Gomez to become CFO

German COVID-19 vaccine maker BioNTech said on Monday that Ramon Zapata-Gomez will become its new finance chief from July 1.

5 days ago · benzinga.com

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Novartis AG NVS agreed to acquire Regulus Therapeutics Inc. RGLS on Wednesday for an initial payment of $7.00 per share in cash or $0.8 billion.

4 days ago · zacks.com

Why Novartis (NVS) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

4 days ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

4 days ago · seekingalpha.com

Novartis: Guidance 2025 Raised To Top End Of Prior Range - Buy Confirmed

Novartis' Q1 2025 results validate our investment thesis. They showcase double-digit sales growth and robust margins, reinforcing our overweight position. Novartis announced a $23 billion US investmen...

4 days ago · wsj.com

Novartis to Acquire Regulus in $1.7 Billion Deal

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.

4 days ago · reuters.com

Novartis to buy Regulus Therapeutics for up to $1.7 billion

Swiss drugmaker Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion to gain access to its experimental kidney disease drug, the California-based drug developer said on Wednesday.

6 days ago · youtube.com

We have put ourselves in the right position to manage tariffs: Novartis CEO

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings.

6 days ago · youtube.com

Novartis CEO on minimizing the impact of potential tariffs on the pharmaceutical industry

Vasant Narasimhan, Novartis CEO, discusses the impact of potential tariffs.

6 days ago · seekingalpha.com

Novartis AG (NVS) Q1 2025 Earnings Call Transcript

Novartis AG (NYSE:NVS ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Sloan Simpson - Head of Investor Relations Vas Narasimhan - CEO Harry Kirsch - CFO Conference Ca...

Load More News